Clearside Biomedical, Inc., a private ophthalmic device and pharmaceutical company based in Alpharetta, Georgia, USA, have announced receipt of a $7.9M investment and a partnership… Read More »Clearside Biomedical receives $8M boost to develop ocular microneedle technology
iCo Therapeutics Inc., a Vancouver based re-profiling development company, have announced that they have exceeded their patient recruitment targets for a phase II DME clinical… Read More »iCo Therapeutics Inc., progresses antisense treatment for DME market
Applied Genetic Technologies Corporation, Inc., (AGTC), a private biotechnology company developing therapies for rare retinal disorders, has announced the closing of a Series B $37.5M… Read More »AGTC raises $37.5M in venture funding to support development of two orphan ophthalmic products
In its second restructuring of FY2012, QLT Inc., (NASDAQ: QLTI) a Canadian based biotechnology company headquartered in Vancouver, has announced that it is to reduce… Read More »QLT Inc lays off over 40% of employees as company refocuses on oral synthetic retinoid product.
Regeneron Inc., moves full steam ahead on European approval of Eylea (aflibercept) Regeneron Inc., (Tarrytown, New York; NASDAQ:REGN) moved up $0.47 to $176.55 per share… Read More »Regeneron Inc., moves full steam ahead on European approval of Eylea (aflibercept)
Regeneron Inc., (Tarrytown, New York; NASDAQ:REGN) have announced third quarter net product sales of $244 million for Eylea (aflibercept) bringing total sales of the ocular… Read More »Regeneron Inc., increases 2012 sales forecast for Eylea to between $790 and $815 million
Queen’s University Belfast (QUB) has announced the receipt of a £32 million (EUR39.7M) investment to establish a Centre for Experimental Medicine. The new research facility… Read More »Major investment in Queen’s University set to benefit retinal and diabetic research
Allergan supports DARPin technology through license and option agreements with Molecular Partners Allergan Inc., (NYSE:AGN) and Molecular Partners AG, a privately owned Swiss company, have… Read More »Allergan supports DARPin technology through license and option agreements with Molecular Partners
A Dutch based company, “to-BBB”, established to develop drug delivery capabilities across the blood brain barrier, has announced the receipt of EURO1.25M in funding from… Read More »Dutch company
LPath, Inc (OTCBB:LPTN, San Diego, USA), a lipid based antibody therapeutics company, has resumed dosing of their ocular formulation of the humanized monoclonal anti-S1P antibody,… Read More »LPath resumes dosing of iSONEP in the Phase II Nexus trial for wet AMD following lift of FDA clinical hold